世界のインスリングラルギン＆リスプロ市場予測（～2028年）：ブランド薬、バイオシミラー薬

• 英文タイトル：Global Insulin Glargine and Lispro Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8860 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

インスリングラルギン＆リスプロ市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のインスリングラルギン＆リスプロの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 インスリングラルギン＆リスプロ市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・ブランド薬、バイオシミラー薬 用途別セグメントは次のように区分されます。 ・タイプI糖尿病、タイプII糖尿病 世界のインスリングラルギン＆リスプロ市場の主要な市場プレーヤーは以下のとおりです。 ・Sanofi S.A、Eli Lilly and Company、Biocon Limited、Cipla Limited、Gan & Lee Pharmaceutical Ltd.、Julphar Diabetes LLC、Merck & Co.、Novo Nordisk A/S、SAJA Pharmaceuticals、Wockhardt Ltd. 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、インスリングラルギン＆リスプロ製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なインスリングラルギン＆リスプロメーカーの企業概要、2019年～2022年までのインスリングラルギン＆リスプロの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なインスリングラルギン＆リスプロメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別インスリングラルギン＆リスプロの販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までのインスリングラルギン＆リスプロの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのインスリングラルギン＆リスプロ市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、およびインスリングラルギン＆リスプロの産業チェーンを掲載しています。 ・第13、14、15章では、インスリングラルギン＆リスプロの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sanofi S.A、Eli Lilly and Company、Biocon Limited、Cipla Limited、Gan & Lee Pharmaceutical Ltd.、Julphar Diabetes LLC、Merck & Co.、Novo Nordisk A/S、SAJA Pharmaceuticals、Wockhardt Ltd. ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：ブランド薬、バイオシミラー薬 ・用途別分析2017年-2028年：タイプI糖尿病、タイプII糖尿病 ・インスリングラルギン＆リスプロの北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・インスリングラルギン＆リスプロのヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・インスリングラルギン＆リスプロのアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・インスリングラルギン＆リスプロの南米市場規模2017年-2028年：ブラジル、アルゼンチン ・インスリングラルギン＆リスプロの中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Insulin Glargine and Lispro market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Insulin Glargine and Lispro market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Type I Dibetes accounting for % of the Insulin Glargine and Lispro global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Branded Drug segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Eli Lilly and Company, Biocon Limited, Cipla Limited, and Gan & Lee Pharmaceutical Ltd., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Insulin Glargine and Lispro market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Branded Drug
Biosimilar Drug
Market segment by Application can be divided into
Type I Dibetes
Type II Dibetes
The key market players for global Insulin Glargine and Lispro market are listed below:
Sanofi S.A
Eli Lilly and Company
Biocon Limited
Cipla Limited
Gan & Lee Pharmaceutical Ltd.
Julphar Diabetes LLC
Merck & Co.
Novo Nordisk A/S
SAJA Pharmaceuticals
Wockhardt Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Insulin Glargine and Lispro product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Insulin Glargine and Lispro, with price, sales, revenue and global market share of Insulin Glargine and Lispro from 2019 to 2022.
Chapter 3, the Insulin Glargine and Lispro competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Insulin Glargine and Lispro breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Insulin Glargine and Lispro market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Insulin Glargine and Lispro.
Chapter 13, 14, and 15, to describe Insulin Glargine and Lispro sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Insulin Glargine and Lispro Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Insulin Glargine and Lispro Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Branded Drug
1.2.3 Biosimilar Drug
1.3 Market Analysis by Application
1.3.1 Overview: Global Insulin Glargine and Lispro Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Type I Dibetes
1.3.3 Type II Dibetes
1.4 Global Insulin Glargine and Lispro Market Size & Forecast
1.4.1 Global Insulin Glargine and Lispro Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Insulin Glargine and Lispro Sales in Volume (2017-2028)
1.4.3 Global Insulin Glargine and Lispro Price (2017-2028)
1.5 Global Insulin Glargine and Lispro Production Capacity Analysis
1.5.1 Global Insulin Glargine and Lispro Total Production Capacity (2017-2028)
1.5.2 Global Insulin Glargine and Lispro Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Insulin Glargine and Lispro Market Drivers
1.6.2 Insulin Glargine and Lispro Market Restraints
1.6.3 Insulin Glargine and Lispro Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi S.A
2.1.1 Sanofi S.A Details
2.1.2 Sanofi S.A Major Business
2.1.3 Sanofi S.A Insulin Glargine and Lispro Product and Services
2.1.4 Sanofi S.A Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Eli Lilly and Company
2.2.1 Eli Lilly and Company Details
2.2.2 Eli Lilly and Company Major Business
2.2.3 Eli Lilly and Company Insulin Glargine and Lispro Product and Services
2.2.4 Eli Lilly and Company Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Biocon Limited
2.3.1 Biocon Limited Details
2.3.2 Biocon Limited Major Business
2.3.3 Biocon Limited Insulin Glargine and Lispro Product and Services
2.3.4 Biocon Limited Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Cipla Limited
2.4.1 Cipla Limited Details
2.4.2 Cipla Limited Major Business
2.4.3 Cipla Limited Insulin Glargine and Lispro Product and Services
2.4.4 Cipla Limited Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Gan & Lee Pharmaceutical Ltd.
2.5.1 Gan & Lee Pharmaceutical Ltd. Details
2.5.2 Gan & Lee Pharmaceutical Ltd. Major Business
2.5.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product and Services
2.5.4 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Julphar Diabetes LLC
2.6.1 Julphar Diabetes LLC Details
2.6.2 Julphar Diabetes LLC Major Business
2.6.3 Julphar Diabetes LLC Insulin Glargine and Lispro Product and Services
2.6.4 Julphar Diabetes LLC Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Merck & Co.
2.7.1 Merck & Co. Details
2.7.2 Merck & Co. Major Business
2.7.3 Merck & Co. Insulin Glargine and Lispro Product and Services
2.7.4 Merck & Co. Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Novo Nordisk A/S
2.8.1 Novo Nordisk A/S Details
2.8.2 Novo Nordisk A/S Major Business
2.8.3 Novo Nordisk A/S Insulin Glargine and Lispro Product and Services
2.8.4 Novo Nordisk A/S Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 SAJA Pharmaceuticals
2.9.1 SAJA Pharmaceuticals Details
2.9.2 SAJA Pharmaceuticals Major Business
2.9.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Product and Services
2.9.4 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Wockhardt Ltd.
2.10.1 Wockhardt Ltd. Details
2.10.2 Wockhardt Ltd. Major Business
2.10.3 Wockhardt Ltd. Insulin Glargine and Lispro Product and Services
2.10.4 Wockhardt Ltd. Insulin Glargine and Lispro Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Insulin Glargine and Lispro Breakdown Data by Manufacturer
3.1 Global Insulin Glargine and Lispro Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Insulin Glargine and Lispro Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Insulin Glargine and Lispro
3.4 Market Concentration Rate
3.4.1 Top 3 Insulin Glargine and Lispro Manufacturer Market Share in 2021
3.4.2 Top 6 Insulin Glargine and Lispro Manufacturer Market Share in 2021
3.5 Global Insulin Glargine and Lispro Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Insulin Glargine and Lispro Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Insulin Glargine and Lispro Market Size by Region
4.1.1 Global Insulin Glargine and Lispro Sales in Volume by Region (2017-2028)
4.1.2 Global Insulin Glargine and Lispro Revenue by Region (2017-2028)
4.2 North America Insulin Glargine and Lispro Revenue (2017-2028)
4.3 Europe Insulin Glargine and Lispro Revenue (2017-2028)
4.4 Asia-Pacific Insulin Glargine and Lispro Revenue (2017-2028)
4.5 South America Insulin Glargine and Lispro Revenue (2017-2028)
4.6 Middle East and Africa Insulin Glargine and Lispro Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Insulin Glargine and Lispro Sales in Volume by Type (2017-2028)
5.2 Global Insulin Glargine and Lispro Revenue by Type (2017-2028)
5.3 Global Insulin Glargine and Lispro Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Insulin Glargine and Lispro Sales in Volume by Application (2017-2028)
6.2 Global Insulin Glargine and Lispro Revenue by Application (2017-2028)
6.3 Global Insulin Glargine and Lispro Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Insulin Glargine and Lispro Sales by Type (2017-2028)
7.2 North America Insulin Glargine and Lispro Sales by Application (2017-2028)
7.3 North America Insulin Glargine and Lispro Market Size by Country
7.3.1 North America Insulin Glargine and Lispro Sales in Volume by Country (2017-2028)
7.3.2 North America Insulin Glargine and Lispro Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Insulin Glargine and Lispro Sales by Type (2017-2028)
8.2 Europe Insulin Glargine and Lispro Sales by Application (2017-2028)
8.3 Europe Insulin Glargine and Lispro Market Size by Country
8.3.1 Europe Insulin Glargine and Lispro Sales in Volume by Country (2017-2028)
8.3.2 Europe Insulin Glargine and Lispro Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Insulin Glargine and Lispro Sales by Type (2017-2028)
9.2 Asia-Pacific Insulin Glargine and Lispro Sales by Application (2017-2028)
9.3 Asia-Pacific Insulin Glargine and Lispro Market Size by Region
9.3.1 Asia-Pacific Insulin Glargine and Lispro Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Insulin Glargine and Lispro Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Insulin Glargine and Lispro Sales by Type (2017-2028)
10.2 South America Insulin Glargine and Lispro Sales by Application (2017-2028)
10.3 South America Insulin Glargine and Lispro Market Size by Country
10.3.1 South America Insulin Glargine and Lispro Sales in Volume by Country (2017-2028)
10.3.2 South America Insulin Glargine and Lispro Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Insulin Glargine and Lispro Sales by Type (2017-2028)
11.2 Middle East & Africa Insulin Glargine and Lispro Sales by Application (2017-2028)
11.3 Middle East & Africa Insulin Glargine and Lispro Market Size by Country
11.3.1 Middle East & Africa Insulin Glargine and Lispro Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Insulin Glargine and Lispro Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Insulin Glargine and Lispro and Key Manufacturers
12.2 Manufacturing Costs Percentage of Insulin Glargine and Lispro
12.3 Insulin Glargine and Lispro Production Process
12.4 Insulin Glargine and Lispro Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Insulin Glargine and Lispro Typical Distributors
13.3 Insulin Glargine and Lispro Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---